Natera (NASDAQ:NTRA) CFO Michael Burkes Brophy Sells 1,178 Shares of Company Stock

Natera, Inc. (NASDAQ:NTRA) CFO Michael Brophy sold 1,178 shares of the business’s stock in a transaction dated Wednesday, October 28th. The shares were sold at an average price of $426.46, for a total transaction of $502,369.88. Following the completion of the sale, the chief financial officer owned 48,480 shares in the company, valued at approximately $20,674,780.80. This trade represents a 2.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Burkes Brophy also recently made the following trade(s):

• On Friday, October 30th, Michael Brophy sold 1,906 shares of Natera stock. The stock was sold at an average price of $425.55, for a total transaction of $811,098.30.
• On Wednesday, October 28th, Michael Brophy sold 1,198 shares of Natera stock. The stock was sold at an average price of $426.34, for a total value of $510,755.32.
• On Tuesday, October 27th, Michael Brophy sold 781 shares of Natera stock. The stock was sold at an average price of $406.00, for a total transaction of $317,086.00.
• On Tuesday, August 4th, Michael Brophy sold 478 shares of Natera stock. The shares were sold at an average price of $274.22, for a total transaction of $131,077.16.

Natera Price Performance

Shares of NTRA stock opened at $414.30 on Monday. The business’s fifty day moving average price is $377.06 and its 200 day moving average price is $266.44. Natera, Inc. has a 1-year low of $181.00 and a 1-year high of $437.41. The firm has a market capitalization of $59.72 billion, a PE ratio of -304.63 and a beta of 1.55.

Natera (NASDAQ:NTRA) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.47) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.02. The company had revenue of $752.75 million during the quarter, compared to analysts’ expectations of $661.24 million. Natera had a negative net margin of 7.11% and a negative return on equity of 11.38%. The firm’s quarterly revenue was up 37.7% compared to the same quarter last year. During the same period last year, the company posted ($0.74) earnings per share. Equities research analysts expect that Natera, Inc. will post -1.14 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of NTRA. Trust Co. of Vermont acquired a new position in Natera during the 2nd quarter valued at about $26,000. Elevation Wealth Partners LLC purchased a new position in shares of Natera during the 2nd quarter valued at $30,000. Continuum Advisory LLC acquired a new position in Natera during the second quarter worth $33,000. International Assets Investment Management LLC boosted its stake in Natera by 132.9% during the 1st quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 97 shares during the period. Finally, Rakuten Securities Inc. acquired a new position in shares of Natera during the second quarter valued at about $35,000. 99.90% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of analysts recently commented on NTRA shares. TD Cowen increased their price objective on Natera from $340.00 to $480.00 and gave the company a “buy” rating in a research note on Tuesday, October 13th. Robert W. Baird set a $348.00 price objective on Natera in a report on Friday, August 7th. Zacks Research cut Natera from a “hold” rating to a “strong sell” rating in a report on Friday, October 16th. Piper Sandler lifted their price objective on Natera from $249.00 to $363.50 and gave the company an “overweight” rating in a research note on Wednesday, August 12th. Finally, Morgan Stanley increased their target price on shares of Natera from $355.00 to $435.00 and gave the stock an “overweight” rating in a research report on Monday, October 12th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $394.31.

About Natera

Natera, Inc is a diagnostics company that develops and commercializes molecular testing services designed to provide personalized genetic and genomic information. Its tests are used across reproductive health, oncology and organ transplantation, with the company combining next-generation sequencing and bioinformatics to analyze DNA and monitor disease-related signals.

In reproductive health, Natera offers Panorama noninvasive prenatal screening, Horizon carrier screening and Vistara single-gene disorder screening.